On site signing ceremony for strategic cooperation
On April 18th, 2024, Guangdong Pulse Medical Technology Co., Ltd. and Johnson&Johnson Medical Technology officially signed a strategic cooperation agreement for left atrial appendage occlusion device system products. Both parties announced that they will work together to deepen long-term cooperation in the field of left atrial appendage occlusion technology, bringing more benefits to tens of thousands of Chinese atrial fibrillation patients with more diverse and effective atrial fibrillation treatment solutions.
Xue Fei, member of the Party Working Committee and Deputy Director of the Management Committee of the High tech Zone, Zhang Jinghua, a second level researcher of the High tech Zone, Cao Xiaoli, Director of the Market Supervision Administration of Zhuhai High tech Zone, and Zou Tao, Deputy Director of the Science and Technology Industry Bureau of the High tech Zone, attended the signing ceremony. At the ceremony, the leaders of the High tech Zone highly praised the achievements of Pulse Medical, vigorously developing the medical industry in Zhuhai, especially the high-end medical industry. In this regard, Pulse Medical has gradually become a banner of cardiovascular medical equipment in Zhuhai. At the same time, they also hope that Pulse Medical Technology will seize the opportunity to carry out deep cooperation with Johnson&Johnson Medical Technology, support and promote each other, actively promote the aggregation and integration of innovative resources at home and abroad, and enable patients to enjoy more convenient, accessible and high-quality medical resources.
Ruan Chengmin, Chairman of Pulse Medical, said, "Pulse Medical has been focusing on the research and innovation of high-end implantable medical devices in the field of cardiovascular diseases for the past decade. In this strategic cooperation, both parties will adhere to the principle of mutual trust and win-win, guided by clinical needs, and leverage their respective professional advantages in the cardiovascular field. Through strong cooperation and deep integration, we will jointly enhance our core competitiveness and achieve business upgrading. In the future, both parties will explore broader markets through complementary resources, markets, and technologies, continuously improve their market competitiveness and social influence, promote high-quality development, achieve mutual benefit and win-win goals, and work together to provide more high-quality innovative medical and health products to serve clinical and patients
Atrial fibrillation is one of the common rapid arrhythmias in clinical practice, and thrombotic complications, especially ischemic stroke, are the main cause of death and disability in atrial fibrillation patients, bringing a heavy burden to society and patients' families. As a local high-tech enterprise dedicated to the field of cardiovascular treatment, Pulse Medical has always been deeply rooted in the "medical engineering integration" model. The company's R&D team works closely with top interventional medical experts in the field of structural heart disease to accurately grasp the real clinical needs and create a series of high-quality products for structural heart disease. Among them, the company's star product "Lefear® Lefear Occluder System" is the world's first "double disc internal plug" left atrial appendage occluder system, which not only has many advantages of internal plug and external cover occluders, but also considers the morphological characteristics of Chinese patients' left atrial appendage and the surgical habits of Chinese surgeons. It has multiple advantages such as dual fixation, dual occlusion,PDL≤3mm, multiple model selection, and simple operation.
This strategic cooperation is just a starting point. In the future, the company will continue to accelerate its own innovation pace, allowing more patients to enjoy high-quality local medical innovation results in the first time! By continuously promoting the landing and transformation of cardiovascular medical technology, creating more leading technological innovation products, helping the high-quality development of the medical device industry, and making greater and more sustainable contributions to the human cardiovascular health cause!